New Drug Combinations for Relapsed Marginal Zone Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests three different treatment combinations using new drugs (mosunetuzumab alone, or combined with zanubrutinib or polatuzumab vedotin) for marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to find which combination works best and is safest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have histologically confirmed (biopsy-proven) marginal zone lymphoma that is CD20-positive, including splenic, nodal, or extranodal types (but not gastrointestinal-only or skin-only disease)
- Your lymphoma has come back or stopped responding after at least one prior CD20-targeted therapy (such as rituximab or similar antibody treatments)
- You have measurable disease on imaging (PET-CT preferred, or CT scan) taken within 42 days before joining
- You have symptoms or signs that your doctor believes warrant treatment, such as fevers, night sweats, weight loss, enlarged lymph nodes, or organ dysfunction
- Your blood counts and organ function (liver, kidney, heart) are adequate enough for treatment, with some flexibility based on your specific disease involvement
- You are at least 18 years old and able to care for yourself with minimal assistance (performance status 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as a first treatment for people with advanced marginal zone lymphoma. The goal is to see if this combination can help control the cancer without the need for chemotherapy.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Hear when a new Recurrent Nodal Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.